Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03000179 · OUTCOME

Progression Free Survival

Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma · Source last updated 2022-04-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
On-study date to lesser of date of progression or date of death from any cause measured up to 3 years after treatment

What was measured

On-study date until disease progression or death. Progression is \>= 20% increase in the sum of diameters of target lesions or non-target lesions, or appearance of new lesions.

Analysis population: all participants

Groups in this outcome

Avelumab Monotherapy

Participants receive avelumab by IV infusion following pretreatment with H1 blockers and acetaminophen once every 2 weeks. Avelumab: Avelumab through a vein once every 2 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Avelumab Monotherapy8

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Avelumab Monotherapy3.4Not reported3.0NAInsufficient number of patients with progression.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Insufficient number of patients with progression.
        group Id
        OG000
        lower Limit
        3.0
        upper Limit
        NA
        value
        3.4
denoms
  1. counts
    1. group Id
      OG000
      value
      8
    units
    Participants
description
On-study date until disease progression or death. Progression is \>= 20% increase in the sum of diameters of target lesions or non-target lesions, or appearance of new lesions.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants receive avelumab by IV infusion following pretreatment with H1 blockers and acetaminophen once every 2 weeks. Avelumab: Avelumab through a vein once every 2 weeks
    id
    OG000
    title
    Avelumab Monotherapy
param Type
MEDIAN
population Description
all participants
reporting Status
POSTED
time Frame
On-study date to lesser of date of progression or date of death from any cause measured up to 3 years after treatment
title
Progression Free Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice